Agenus: GSK's ZOE-50 Phase 3 Study Meets Primary Endpoint - Quick Facts

(RTTNews) - Agenus Inc. (AGEN) announced that its partner GlaxoSmithKline (GSK.L, GSK) reported that the ZOE-50 Phase 3 study met its primary endpoint. Analysis of the primary endpoint showed that HZ/su reduced the risk of shingles by 97.2 percent in adults aged 50 years and older compared to placebo. Agenus is entitled to receive royalties on potential commercial sales of HZ/su.

HZ/su is a candidate vaccine that combines gE, a protein found on the varicella-zoster virus that causes shingles, with GSK's Adjuvant System, AS01B, which serves to stimulate a stronger immunological response to the vaccine.